LGP has announced it will exclusively supply medicinal cannabis oil products to enrolled patients in the QUality of life Evaluation Study, commonly known as The QUEST Initiative.
LGP will also provide funding costs for the initiative, which is being conducted by researchers at the University of Sydney.
The study aims to be one of the world’s largest longitudinal studies investigating the quality of life and health economics of patients with chronic disease who are prescribed medicinal cannabis.
FastForward has a 0.9% interest in the issued stock of LGP after participating in last week’s share placing by the medicinal cannabis business.
“Little Green Pharma is one of our newest investments in the medical cannabis space and we are delighted that it is already delivering such strong news flow. The QUEST Initiative aims to have at least 2,100 patients by 30 June 2021, which is a very significant number, and it is excellent to hear that Little Green Pharma is involved with the exclusive supply of medical cannabis oil products as well as providing funding for study costs,” said Ed McDermott, the chief executive officer of FastForward.
Shares in the investment firm were up 24% at 14.4p midway through the morning trading session.